Spots Global Cancer Trial Database for Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours
Official Title: An Open, Phase I, Dose Escalation Study of the Monoclonal Antibody TB-403 Directed Against PlGF, Given as Multiple IV-doses to Patients With Solid Tumors.
Study ID: NCT00702494
Conditions
Interventions
Study Description
Brief Summary: TB-403 is a monoclonal antibody directed against Placental Growth Factor (PlGF). The antibody binds to PlGF and inhibits the binding to it's receptor, VEGF-1. By preventing this binding, growth of tumor vessels are inhibited and tumor growth prevented. In this study we are investigating the tolerability and safety of TB-403 in patients with solid tumors who receives multiple intravenous doses of TB-403.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Onkologisk Klinik 5072 Finsencentret Rigshospitalet, Copenhagen, , Denmark
Onkologisk Afdeling 54B1 Herlev Hospital, Herlev, , Denmark
Contact Details
Name: Ulrik Lassen, MD, PhD
Affiliation: Rigshospitalet, Denmark
Role: STUDY_CHAIR
Name: Lena Winstedt, PhD
Affiliation: BioInvent International AB
Role: STUDY_DIRECTOR
Name: Dorthe Nielsen, MD, PhD
Affiliation: Herlev Hospital, Herlev, Denmark
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
